Welcome to Paid Research Studies




  • Condition:   Parkinson Disease
    Intervention:   Drug: sargramostim
    Sponsor:   University of Nebraska
    Recruiting

  • Condition:   Iron Deficiency
    Intervention:   Dietary Supplement: BioFe
    Sponsors:   Sidero Bioscience, LLC;   Milton S. Hershey Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Squamous Cell Carcinoma
    Interventions:   Drug: Aldoxorubicin HCl;   Biological: ETBX-011;   Biological: ETBX-021;   Biological: ETBX-051;   Biological: ETBX-061;   Biological: GI-4000;   Biological: GI-6207;   Biological: GI-6301;   Biological: haNK for infusion;   Drug: Avelumab;   Drug: bevacizumab;   Drug: Capecitabine;   Drug: Cetuximab;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: nab-Paclitaxel;   Drug: Necitumumab;   Procedure: SBRT;   Biological: N-803
    Sponsor:   NantKwest, Inc.
    Recruiting

  • Condition:   Triple Negative Breast Cancer
    Interventions:   Drug: Aldoxorubicin HCl;   Biological: ALT-803;   Biological: ETBX-011;   Biological: ETBX-051;   Biological: ETBX-061;   Biological: GI-4000;   Biological: GI-6207;   Biological: GI-6301;   Biological: haNK for Infusion;   Biological: avelumab;   Biological: bevacizumab;   Drug: Capecitabine;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: nab-Paclitaxel;   Procedure: SBRT
    Sponsor:   NantKwest, Inc.
    Recruiting

  • Conditions:   Hepatocellular Carcinoma Non-resectable;   Hepatocellular Carcinoma Recurrent
    Interventions:   Biological: ETBX-011;   Biological: GI-4000;   Biological: haNK for infusion;   Biological: avelumab;   Drug: Capecitabine;   Drug: Cyclophosphamide;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: nab-Paclitaxel;   Drug: Sorafenib;   Procedure: SBRT;   Biological: Aldoxorubicin hydrochloride;   Biological: ETBX-051;   Biological: ETBX-061;   Biological: GI-6207;   Biological: GI-6301;   Drug: Cetuximab;   Biological: N-803
    Sponsor:   NantKwest, Inc.
    Recruiting

  • Condition:   Metastatic Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel;   Drug: Aldoxorubicin HCl;   Biological: ALT-803;   Biological: ETBX-011;   Biological: ETBX-021;   Biological: ETBX-051;   Biological: ETBX-061;   Biological: GI-4000;   Biological: GI-6207;   Biological: GI-6301;   Biological: haNK;   Drug: Avelumab;   Drug: Bevacizumab;   Drug: Capecitabine;   Drug: Cyclophosphamide;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Oxaliplatin
    Sponsor:   NantKwest, Inc.
    Not yet recruiting

  • Condition:   Triple Negative Breast Cancer (TNBC)
    Interventions:   Drug: Leucovorin;   Drug: 5-Fluorouracil;   Drug: Aldoxorubicin HCl;   Drug: nab-Paclitaxel;   Biological: ETBX-011;   Biological: ETBX-051;   Biological: ETBX-061;   Biological: GI-4000;   Biological: GI-6207;   Biological: GI-6301;   Drug: Avelumab;   Biological: ALT-803;   Biological: haNK;   Drug: Cyclophosphamide;   Drug: Doxorubicin HCL;   Drug: paclitaxel
    Sponsor:   NantKwest, Inc.
    Not yet recruiting